Boston Scientific (BSX) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $45.29 +0.76%
Revenue Growth %: +6.3%
Financial Fact:
Income (loss) before income taxes: 257M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +6.3%
Financial Fact:
Income (loss) before income taxes: 257M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.75, $0.08 better than the analyst estimate of $0.67. Revenue for the quarter came in at $4.66 billion versus the consensus estimate of $4.57 billion.
GUIDANCE:
Boston Scientific sees FY2025 EPS of $2.87-$2.94, versus the consensus of $2.86.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Pfizer reaffirms 2026 guidance after CFO transition news
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
